Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 113 clinical trials
Intravesical Photodynamic Therapy (PDT) in BCG Refractory/Intolerant Non-Muscle Invasive Bladder Cancer (NMIBC) Patients

This is a phase II, open-label, single-arm, multi-center Study conducted in Canada, the United States and internationally. Patients with NMIBC CIS with or without resected papillary disease (Ta, T1) that are considered bacillus Calmette-Guerin (BCG)-Unresponsive or who are intolerant to BCG therapy. BCG-Unresponsive is at least one of the following: …

  • 63 views
  • 24 Jan, 2021
  • 4 locations
Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer

A multi-center, open-label, phase II clinical study of metformin in up to evaluable 49 patients with low-grade NMIBC with the aim to determine the overall response to administration of oral metformin for 3 months in a marker tumour deliberately left following transurethral resection of multiple, papillary NMIBC tumours.

bladder carcinoma
carcinoma
invasive bladder cancer
transurethral resection
bladder cancer
  • 1 views
  • 01 Feb, 2021
  • 1 location
18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy

This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of muscle invasive bladder

carcinoma
metastasis
invasive bladder cancer
radiopharmaceuticals
bladder cancer
  • 1 views
  • 23 Jan, 2021
  • 1 location
Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis

extensive experience in treatment of non-muscle invasive bladder cancer with BCG Moreau, also BCG Moreau Rio de Janeiro make same immunological reaction as TICE, but with less adverse events. Thus, BCG

mitomycin
carcinoma
invasive bladder cancer
chemotherapy drug
bladder cancer
  • 20 views
  • 23 Jan, 2021
  • 22 locations
Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy

The purpose of this study is to investigate the effect synchronous use of nivolumab in addition to chemoradiotherapy in patients withnon-metastatic MIBC who are not candidates for radical cystectomy

bladder carcinoma
carcinoma
TURB
invasive bladder cancer
bladder cancer
  • 9 views
  • 26 Jan, 2021
  • 1 location
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

The purpose of this study is to find out what effects durvalumab has on bladder cancer, combined with treatment after completion of surgery, chemotherapy and radiotherapy.

bladder carcinoma
neutrophil count
mitomycin
carcinoma
durvalumab
  • 47 views
  • 24 Feb, 2021
  • 28 locations
Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

carcinoma and a cohort of patients with muscle invasive bladder cancer. Secondary 1A. To assess the proportion of patients who achieve pathological CR with daratumumab

gilbert's disease
metastasis
bladder cancer
primary tumor
cancer
  • 21 views
  • 22 Jan, 2021
  • 2 locations
Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer

This is a phase 2, single arm, open label trial to evaluate the rate of failure free survival at 2 years after start of chemoradiation with adjuvant nivolumab in adult subjects who undergo chemoradiation for localized bladder cancer.

neutrophil count
carcinoma
cancer treatment
invasive bladder cancer
transurethral resection
  • 70 views
  • 27 Jan, 2021
  • 1 location
Study of CAbozantinib in Combination With AtezolizumaB for Muscle-Invasive BladdEr Cancer (ABATE)

This is an open-label phase II study assessing the activity of cabozantinib combined with atezolizumab in patients with resectable muscle-invasive urothelial carcinoma who are ineligible for cisplatin-based therapy or decline cisplatin-based therapy. Each cycle equals 21 days. The dose of atezolizumab is 1200 mg IV flat dose every 3 weeks …

neutrophil count
carcinoma
aptt
metastasis
invasive bladder cancer
  • 0 views
  • 28 Jan, 2021
  • 3 locations
Intravesical Gemcitabine and Docetaxel for BCG na ve Non-muscle Invasive Bladder Cancer

invasive bladder cancer (NMIBC). All participants will receive an induction course of gemcitabine/docetaxel instillations followed by maintenance instillations if initial efficacy is seen. In addition to

carcinoma
gemcitabine
intravesical bcg
invasive bladder cancer
hysterectomy
  • 0 views
  • 25 Jan, 2021
  • 1 location